Do analysts recommend PDEX or SKYA?

Pro-Dex currently has a consensus target price of $70.00, indicating a potential upside of 8.75%. Given Pro-Dex's stronger consensus rating and higher probable upside, analysts clearly believe Pro-Dex is more favorable than SkyAI, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pro-Dex 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 SkyAI, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to PDEX or SKYA?

In the previous week, SkyAI, Inc. Common Stock had 3 more articles in the media than Pro-Dex. MarketBeat recorded 5 mentions for SkyAI, Inc. Common Stock and 2 mentions for Pro-Dex. Pro-Dex's average media sentiment score of 0.00 equaled SkyAI, Inc. Common Stock'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pro-Dex 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SkyAI, Inc. Common Stock 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate RXST or SKYA?

RxSight presently has a consensus price target of $9.44, indicating a potential upside of 99.67%. Given RxSight's stronger consensus rating and higher probable upside, research analysts clearly believe RxSight is more favorable than SkyAI, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RxSight 3 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 1.93 SkyAI, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate SKYA or SMTI?

Sanara MedTech has a consensus target price of $34.00, indicating a potential upside of 54.41%. Given Sanara MedTech's stronger consensus rating and higher possible upside, analysts clearly believe Sanara MedTech is more favorable than SkyAI, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SkyAI, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sanara MedTech 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60

Do analysts prefer APYX or SKYA?

Apyx Medical currently has a consensus target price of $6.50, suggesting a potential upside of 58.15%. Given Apyx Medical's stronger consensus rating and higher possible upside, equities analysts plainly believe Apyx Medical is more favorable than SkyAI, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apyx Medical 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67 SkyAI, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to APYX or SKYA?

In the previous week, SkyAI, Inc. Common Stock had 2 more articles in the media than Apyx Medical. MarketBeat recorded 5 mentions for SkyAI, Inc. Common Stock and 3 mentions for Apyx Medical. Apyx Medical's average media sentiment score of 0.96 beat SkyAI, Inc. Common Stock's score of 0.00 indicating that Apyx Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apyx Medical 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SkyAI, Inc. Common Stock 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate EMBC or SKYA?

Embecta currently has a consensus price target of $11.00, suggesting a potential upside of 253.70%. Given Embecta's stronger consensus rating and higher possible upside, analysts plainly believe Embecta is more favorable than SkyAI, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Embecta 3 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.40 SkyAI, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor EMBC or SKYA?

In the previous week, Embecta had 12 more articles in the media than SkyAI, Inc. Common Stock. MarketBeat recorded 17 mentions for Embecta and 5 mentions for SkyAI, Inc. Common Stock. SkyAI, Inc. Common Stock's average media sentiment score of 0.00 beat Embecta's score of -0.06 indicating that SkyAI, Inc. Common Stock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Embecta 1 Very Positive mention(s) 0 Positive mention(s) 13 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral SkyAI, Inc. Common Stock 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

SkyAI, Inc. Common Stock (SKYA) Competitors

$1.18 0.00 (0.00%)

As of 06/18/2026 04:00 PM Eastern

Compare

SKYA vs. PDEX, RXST, SMTI, APYX, and EMBC

Should you buy SkyAI, Inc. Common Stock stock or one of its competitors? MarketBeat compares SkyAI, Inc. Common Stock with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SkyAI, Inc. Common Stock include Pro-Dex (PDEX), RxSight (RXST), Sanara MedTech (SMTI), Apyx Medical (APYX), and Embecta (EMBC). These companies are all part of the "medical equipment" industry.

How does SkyAI, Inc. Common Stock compare to Pro-Dex?

Pro-Dex (NASDAQ:PDEX) and SkyAI, Inc. Common Stock (NASDAQ:SKYA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

Pro-Dex has higher revenue and earnings than SkyAI, Inc. Common Stock. SkyAI, Inc. Common Stock is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pro-Dex	$66.59M	3.08	$8.98M	$3.62	17.78
SkyAI, Inc. Common Stock	$200K	249.69	-$282.50M	-$1.63	N/A

Pro-Dex currently has a consensus target price of $70.00, indicating a potential upside of 8.75%. Given Pro-Dex's stronger consensus rating and higher probable upside, analysts clearly believe Pro-Dex is more favorable than SkyAI, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pro-Dex	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
SkyAI, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, SkyAI, Inc. Common Stock had 3 more articles in the media than Pro-Dex. MarketBeat recorded 5 mentions for SkyAI, Inc. Common Stock and 2 mentions for Pro-Dex. Pro-Dex's average media sentiment score of 0.00 equaled SkyAI, Inc. Common Stock'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pro-Dex	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SkyAI, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pro-Dex has a net margin of 16.08% compared to SkyAI, Inc. Common Stock's net margin of 0.00%. Pro-Dex's return on equity of 22.78% beat SkyAI, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pro-Dex	16.08%	22.78%	14.30%
SkyAI, Inc. Common Stock	N/A	-157.91%	-154.40%

15.3% of Pro-Dex shares are owned by institutional investors. Comparatively, 17.2% of SkyAI, Inc. Common Stock shares are owned by institutional investors. 45.9% of Pro-Dex shares are owned by insiders. Comparatively, 20.0% of SkyAI, Inc. Common Stock shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Pro-Dex has a beta of -0.02, meaning that its stock price is 102% less volatile than the broader market. Comparatively, SkyAI, Inc. Common Stock has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market.

Summary

Pro-Dex beats SkyAI, Inc. Common Stock on 11 of the 15 factors compared between the two stocks.

How does SkyAI, Inc. Common Stock compare to RxSight?

RxSight (NASDAQ:RXST) and SkyAI, Inc. Common Stock (NASDAQ:SKYA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

In the previous week, SkyAI, Inc. Common Stock had 5 more articles in the media than RxSight. MarketBeat recorded 5 mentions for SkyAI, Inc. Common Stock and 0 mentions for RxSight. RxSight's average media sentiment score of 0.00 equaled SkyAI, Inc. Common Stock'saverage media sentiment score.

Company	Overall Sentiment
RxSight	Neutral
SkyAI, Inc. Common Stock	Neutral

SkyAI, Inc. Common Stock has a net margin of 0.00% compared to RxSight's net margin of -36.58%. RxSight's return on equity of -17.01% beat SkyAI, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.58%	-17.01%	-15.12%
SkyAI, Inc. Common Stock	N/A	-157.91%	-154.40%

78.8% of RxSight shares are held by institutional investors. Comparatively, 17.2% of SkyAI, Inc. Common Stock shares are held by institutional investors. 10.1% of RxSight shares are held by company insiders. Comparatively, 20.0% of SkyAI, Inc. Common Stock shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

RxSight presently has a consensus price target of $9.44, indicating a potential upside of 99.67%. Given RxSight's stronger consensus rating and higher probable upside, research analysts clearly believe RxSight is more favorable than SkyAI, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93
SkyAI, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

RxSight has higher revenue and earnings than SkyAI, Inc. Common Stock. RxSight is trading at a lower price-to-earnings ratio than SkyAI, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$134.48M	1.46	-$38.94M	-$1.13	N/A
SkyAI, Inc. Common Stock	$200K	249.69	-$282.50M	-$1.63	N/A

RxSight has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market. Comparatively, SkyAI, Inc. Common Stock has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market.

Summary

RxSight beats SkyAI, Inc. Common Stock on 9 of the 15 factors compared between the two stocks.

How does SkyAI, Inc. Common Stock compare to Sanara MedTech?

SkyAI, Inc. Common Stock (NASDAQ:SKYA) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Sanara MedTech has higher revenue and earnings than SkyAI, Inc. Common Stock. Sanara MedTech is trading at a lower price-to-earnings ratio than SkyAI, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SkyAI, Inc. Common Stock	$200K	249.69	-$282.50M	-$1.63	N/A
Sanara MedTech	$103.12M	1.96	-$37.56M	-$3.77	N/A

SkyAI, Inc. Common Stock has a beta of 2.04, meaning that its share price is 104% more volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market.

In the previous week, SkyAI, Inc. Common Stock had 4 more articles in the media than Sanara MedTech. MarketBeat recorded 5 mentions for SkyAI, Inc. Common Stock and 1 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 1.63 beat SkyAI, Inc. Common Stock's score of 0.00 indicating that Sanara MedTech is being referred to more favorably in the news media.

Company	Overall Sentiment
SkyAI, Inc. Common Stock	Neutral
Sanara MedTech	Very Positive

SkyAI, Inc. Common Stock has a net margin of 0.00% compared to Sanara MedTech's net margin of -31.23%. Sanara MedTech's return on equity of -3.19% beat SkyAI, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SkyAI, Inc. Common Stock	N/A	-157.91%	-154.40%
Sanara MedTech	-31.23%	-3.19%	-0.56%

Sanara MedTech has a consensus target price of $34.00, indicating a potential upside of 54.41%. Given Sanara MedTech's stronger consensus rating and higher possible upside, analysts clearly believe Sanara MedTech is more favorable than SkyAI, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SkyAI, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sanara MedTech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

17.2% of SkyAI, Inc. Common Stock shares are owned by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are owned by institutional investors. 20.0% of SkyAI, Inc. Common Stock shares are owned by insiders. Comparatively, 42.0% of Sanara MedTech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Sanara MedTech beats SkyAI, Inc. Common Stock on 10 of the 17 factors compared between the two stocks.

How does SkyAI, Inc. Common Stock compare to Apyx Medical?

Apyx Medical (NASDAQ:APYX) and SkyAI, Inc. Common Stock (NASDAQ:SKYA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

55.3% of Apyx Medical shares are owned by institutional investors. Comparatively, 17.2% of SkyAI, Inc. Common Stock shares are owned by institutional investors. 15.2% of Apyx Medical shares are owned by insiders. Comparatively, 20.0% of SkyAI, Inc. Common Stock shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, SkyAI, Inc. Common Stock had 2 more articles in the media than Apyx Medical. MarketBeat recorded 5 mentions for SkyAI, Inc. Common Stock and 3 mentions for Apyx Medical. Apyx Medical's average media sentiment score of 0.96 beat SkyAI, Inc. Common Stock's score of 0.00 indicating that Apyx Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apyx Medical	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SkyAI, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Apyx Medical currently has a consensus target price of $6.50, suggesting a potential upside of 58.15%. Given Apyx Medical's stronger consensus rating and higher possible upside, equities analysts plainly believe Apyx Medical is more favorable than SkyAI, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apyx Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
SkyAI, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

SkyAI, Inc. Common Stock has a net margin of 0.00% compared to Apyx Medical's net margin of -16.40%. Apyx Medical's return on equity of -88.47% beat SkyAI, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apyx Medical	-16.40%	-88.47%	-14.94%
SkyAI, Inc. Common Stock	N/A	-157.91%	-154.40%

Apyx Medical has higher revenue and earnings than SkyAI, Inc. Common Stock. Apyx Medical is trading at a lower price-to-earnings ratio than SkyAI, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apyx Medical	$52.84M	3.26	-$11.21M	-$0.22	N/A
SkyAI, Inc. Common Stock	$200K	249.69	-$282.50M	-$1.63	N/A

Apyx Medical has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market. Comparatively, SkyAI, Inc. Common Stock has a beta of 2.04, suggesting that its share price is 104% more volatile than the broader market.

Summary

Apyx Medical beats SkyAI, Inc. Common Stock on 11 of the 17 factors compared between the two stocks.

How does SkyAI, Inc. Common Stock compare to Embecta?

Embecta (NASDAQ:EMBC) and SkyAI, Inc. Common Stock (NASDAQ:SKYA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Embecta currently has a consensus price target of $11.00, suggesting a potential upside of 253.70%. Given Embecta's stronger consensus rating and higher possible upside, analysts plainly believe Embecta is more favorable than SkyAI, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	3 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.40
SkyAI, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Embecta had 12 more articles in the media than SkyAI, Inc. Common Stock. MarketBeat recorded 17 mentions for Embecta and 5 mentions for SkyAI, Inc. Common Stock. SkyAI, Inc. Common Stock's average media sentiment score of 0.00 beat Embecta's score of -0.06 indicating that SkyAI, Inc. Common Stock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Embecta	1 Very Positive mention(s)	0 Positive mention(s)	13 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral
SkyAI, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Embecta has higher revenue and earnings than SkyAI, Inc. Common Stock. SkyAI, Inc. Common Stock is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.08B	0.17	$95.40M	$1.90	1.64
SkyAI, Inc. Common Stock	$200K	249.69	-$282.50M	-$1.63	N/A

Embecta has a net margin of 10.73% compared to SkyAI, Inc. Common Stock's net margin of 0.00%. Embecta's return on equity of -23.96% beat SkyAI, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Embecta	10.73%	-23.96%	14.12%
SkyAI, Inc. Common Stock	N/A	-157.91%	-154.40%

Embecta has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, SkyAI, Inc. Common Stock has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market.

93.8% of Embecta shares are held by institutional investors. Comparatively, 17.2% of SkyAI, Inc. Common Stock shares are held by institutional investors. 1.3% of Embecta shares are held by company insiders. Comparatively, 20.0% of SkyAI, Inc. Common Stock shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Embecta beats SkyAI, Inc. Common Stock on 11 of the 15 factors compared between the two stocks.

Get SkyAI, Inc. Common Stock News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SKYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SKYA vs. The Competition

Export

Metric	SkyAI, Inc. Common Stock	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$49.94M	$8.34B	$6.42B	$12.60B
Dividend Yield	N/A	2.56%	2.68%	5.67%
P/E Ratio	-0.72	15.57	24.49	24.42
Price / Sales	249.69	6.69	526.48	110.42
Price / Cash	N/A	17.05	45.07	55.09
Price / Book	0.13	3.28	10.83	6.58
Net Income	-$282.50M	$224.06M	$3.57B	$337.17M
7 Day Performance	5.36%	-1.92%	0.77%	0.87%
1 Month Performance	-36.56%	-0.44%	1.40%	3.29%
1 Year Performance	-77.31%	0.83%	29.35%	36.02%

SkyAI, Inc. Common Stock Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SKYA SkyAI, Inc. Common Stock	0.9583 of 5 stars	$1.18 flat	N/A	-78.3%	$49.94M	$200K	N/A	55
PDEX Pro-Dex	1.993 of 5 stars	$65.00 flat	$70.00 +7.7%	+57.6%	$207.53M	$66.59M	17.96	140	News Coverage Positive News
RXST RxSight	3.0879 of 5 stars	$4.91 -0.8%	$9.44 +92.4%	-65.9%	$204.91M	$134.48M	N/A	220	Positive News
SMTI Sanara MedTech	2.5959 of 5 stars	$22.72 +2.9%	$34.00 +49.6%	-20.3%	$202.43M	$103.12M	N/A	60	Analyst Upgrade
APYX Apyx Medical	2.499 of 5 stars	$4.86 +1.9%	$6.50 +33.7%	+140.4%	$199.74M	$52.84M	N/A	270	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SKYA) was last updated on 6/20/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SkyAI, Inc. Common Stock (SKYA) Competitors

SKYA vs. PDEX, RXST, SMTI, APYX, and EMBC

How does SkyAI, Inc. Common Stock compare to Pro-Dex?

Summary

How does SkyAI, Inc. Common Stock compare to RxSight?

Summary

How does SkyAI, Inc. Common Stock compare to Sanara MedTech?

Summary

How does SkyAI, Inc. Common Stock compare to Apyx Medical?

Summary

How does SkyAI, Inc. Common Stock compare to Embecta?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SKYA vs. The Competition

SkyAI, Inc. Common Stock Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SkyAI, Inc. Common Stock (SKYA) Competitors

SKYA vs. PDEX, RXST, SMTI, APYX, and EMBC

How does SkyAI, Inc. Common Stock compare to Pro-Dex?

Which has better earnings & valuation, PDEX or SKYA?

Do analysts recommend PDEX or SKYA?

Does the media refer more to PDEX or SKYA?

Is PDEX or SKYA more profitable?

Do insiders & institutionals have more ownership in PDEX or SKYA?

Which has more risk and volatility, PDEX or SKYA?

Summary

How does SkyAI, Inc. Common Stock compare to RxSight?

Does the media refer more to RXST or SKYA?

Is RXST or SKYA more profitable?

Do institutionals and insiders have more ownership in RXST or SKYA?

Do analysts rate RXST or SKYA?

Which has better valuation and earnings, RXST or SKYA?

Which has more risk and volatility, RXST or SKYA?

Summary

How does SkyAI, Inc. Common Stock compare to Sanara MedTech?

Which has better valuation and earnings, SKYA or SMTI?

Which has more risk & volatility, SKYA or SMTI?

Does the media favor SKYA or SMTI?

Is SKYA or SMTI more profitable?

Do analysts rate SKYA or SMTI?

Do institutionals & insiders believe in SKYA or SMTI?

Summary

How does SkyAI, Inc. Common Stock compare to Apyx Medical?

Do institutionals and insiders hold more shares of APYX or SKYA?

Does the media refer more to APYX or SKYA?

Do analysts prefer APYX or SKYA?

Is APYX or SKYA more profitable?

Which has preferable valuation & earnings, APYX or SKYA?

Which has more risk & volatility, APYX or SKYA?

Summary

How does SkyAI, Inc. Common Stock compare to Embecta?

Do analysts rate EMBC or SKYA?

Does the media favor EMBC or SKYA?

Which has preferable earnings & valuation, EMBC or SKYA?

Is EMBC or SKYA more profitable?

Which has more volatility and risk, EMBC or SKYA?

Do institutionals & insiders hold more shares of EMBC or SKYA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SKYA vs. The Competition

SkyAI, Inc. Common Stock Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools